Denosumab for Smoldering Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Denosumab for Smoldering Multiple Myeloma (NCT03839459), a na phase 2 study. The primary outcome is Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases..

2. Clinical Question

The study’s stated purpose also includes assessing denosumab’s safety and tolerability and whether it can reduce the risk of progression to multiple myeloma. Those aims need to be distinguished from the primary endpoint as registered: a change in risk category, rather than a direct measurement of progression to multiple myeloma. The secondary outcomes include progression, progression-free survival at 3 years, skeletal-related events, and change in bone mineral density from screening to 1 year.

Because there is no comparator arm, the trial can describe what was recorded among participants in the denosumab group, but it cannot isolate a treatment effect from changes that could occur over time for other reasons. The endpoint result and its uncertainty are not reported in the registry record, so the clinical question cannot be answered from the registered results alone.

3. Trial Design

This is a completed phase 2 study sponsored by the University of Rochester. The registry lists an enrollment of 20 and a single-group model. Allocation is recorded as not applicable, and masking is recorded as none. The listed intervention is denosumab; no comparator group or detailed arm description is recorded.

The study began on 2019-04-19, and the primary completion date is 2022-09-16. These dates describe the registry record’s study timeline; they do not indicate when individual participants were treated or assessed. The status is listed as completed. Completion of a study does not by itself mean that every planned outcome result has been posted.

The primary endpoint is the proportion of participants whose risk category for progression of smoldering multiple myeloma decreased at 1 year. The record defines four risk categories using the count of three specified risk factors: bone marrow plasma cell percentage at least 50, M-protein at least 3g/dL, and an involved-to-uninvolved free light-chain ratio at least 8. The endpoint description does not report how risk-category change was handled for participants with incomplete measurements.

Four secondary outcomes are listed: skeletal-related events, progression to multiple myeloma, progression-free survival at 3 years, and change in bone mineral density from screening to 1 year. The registry records five outcome measures overall, but it does not include posted analyses for these outcomes. The primary and secondary outcome results are not reported in the registry record.

A single-group design can describe changes and events observed among participants who received the intervention. It does not offer the randomized, concurrent control comparison needed to separate those observations from the underlying course of the condition, other care, or measurement variation. The record does not report a protocol-based sample-size justification or detailed analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases., measured over 1 year.

The primary endpoint asks what proportion of participants had a decrease in their smoldering-myeloma progression-risk category at 1 year. The categories are defined by how many of three risk factors are present: bone marrow plasma cell percentage at least 50, M-protein at least 3g/dL, and an involved-to-uninvolved free light-chain ratio at least 8. A category decrease therefore represents a lower category under this specific rule.

This endpoint is a classification-based measure. It summarizes whether risk-factor information moved a participant into a lower category, rather than directly counting progression events. Such a measure can be useful for describing changes in a set of clinically relevant markers over a specified assessment period. It also depends on the measurements used to classify participants and on the boundaries set for each category.

A lower category should not be interpreted as proof that progression was prevented, nor is it identical to remaining free of progression. The registry lists progression to multiple myeloma and progression-free survival at 3 years as separate secondary outcomes, underscoring that these are distinct measures. Their results, like the primary result, are not reported in the registry record.

The endpoint is expressed as a proportion of participants, but the registry record does not report the observed proportion, the number whose category decreased, or an uncertainty interval. It also does not explain how missing risk-factor measurements or ties in classification were handled. Without those details and the endpoint result, the registered definition can be described, but its observed magnitude and precision cannot be assessed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation starts with identifying the type of question and the design used to address it. This study is single-group, with no comparator arm recorded. As a general statistical principle, a before-and-after or within-group description can characterize changes during observation, but it cannot by itself distinguish an intervention effect from other explanations for change. A concurrent comparison group can help with that distinction; a like-for-like control comparison is not available in this record.

What does a proportion describe?

The primary endpoint is a proportion: the share of participants whose risk category decreased at 1 year. A proportion is a summary of a binary classification, in this case whether the specified category decrease occurred. To interpret it, readers need both the numerator (participants meeting the endpoint) and the denominator (participants included in the analysis), as well as a clear account of missing measurements. The endpoint result and these analysis details are not reported in the registry record.

A confidence interval, as a general statistical concept, expresses uncertainty around an estimate. It indicates a range of values compatible with the observed data under the method’s assumptions; it does not guarantee that the true value lies in that range. No confidence interval for the primary endpoint is reported in the registry record. Consequently, its statistical precision cannot be evaluated.

How does the risk category work?

The endpoint classifies participants using three listed risk factors: bone marrow plasma cell percentage at least 50, M-protein at least 3g/dL, and an involved-to-uninvolved free light-chain ratio at least 8. The categories are low risk when none of the listed factors are present, low-intermediate risk when one is present, high-intermediate risk when two are present, and high risk when three are present. A decrease means moving to a lower category under these definitions.

As a general measurement issue, categorical endpoints can be easier to communicate than several separate continuous measurements, but they discard some detail. A measurement close to a threshold may be classified differently from one just across it, even when the underlying values are similar. This is a feature of threshold-based classification, not evidence that the measurements themselves changed substantially. The record does not describe measurement procedures or how uncertainty around the risk factors was addressed.

What can a single-group study estimate?

In general, a single-group study can estimate event frequencies or describe changes among participants observed in that group, provided that the outcome data and analysis population are reported. It does not directly estimate the difference between treatment and control. Because there is no concurrent comparator, changes could reflect the natural course of smoldering multiple myeloma, measurement variation, other care, or factors not recorded in the study summary. This limits causal interpretation even if within-group change is reported.

The registry lists a planning illustration framework based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the target effect is described as a fraction of the observed effect. These are planning assumptions, not a report of the trial’s design. The record does not report the protocol’s sample-size justification. Planning calculations are not observed power, and an illustration based on an observed effect should not be confused with the evidence generated by this single-group trial.

Why do analysis details matter?

For a proportion, the analysis population determines who is counted in the denominator. For a risk-category endpoint, the handling of missing factor measurements can affect whether participants can be classified. The registry record does not report the analysis population, missing-data method, or rules for deriving the category at follow-up. These are not minor reporting details: they determine how an endpoint estimate should be understood and whether it can be reproduced.

Multiple outcomes also require careful interpretation. The registry lists the primary endpoint and secondary measures of skeletal-related events, progression, progression-free survival, and bone mineral density change. When several outcomes are assessed, the chance of at least one apparently notable result can rise if no adjustment or hierarchy is specified. General statistical practice addresses this through a prespecified testing strategy, but such a strategy is not reported in the registry record. No analysis entries are recorded.

Finally, statistical significance and clinical meaning are different questions. A p-value, when reported, describes how compatible data are with a specified null model under stated assumptions; it does not measure the size or importance of an effect. Here, no primary-outcome estimate, confidence interval, or analysis result is reported, so neither the magnitude nor the precision of the endpoint can be assessed.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Denosumab")
n      <- c(15)
events <- c(0)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Denosumab  15  0  0.0  0.0  21.8  0.0  20.4  0.2  20.6

11. Multiplicity, Missing Data and Analysis Populations

The registry lists five outcome measures: the risk-category endpoint at 1 year and secondary outcomes concerning skeletal-related events, progression to multiple myeloma, progression-free survival at 3 years, and bone mineral density change from screening to 1 year. It records no analysis entries. The results for these outcomes are not reported in the registry record.

When a study evaluates multiple outcomes, general statistical reasoning calls for attention to multiplicity. If many hypotheses are tested, some may appear notable by chance alone. Prespecified primary and secondary outcome roles, a testing hierarchy, or an adjustment approach can help readers understand how to interpret findings. The registry record does not report such a plan, so it is not possible to determine how multiplicity was handled.

The record also does not report the analysis population or the method for handling missing endpoint measurements. For the primary endpoint, missing risk-factor data could prevent assigning a category or assessing whether it decreased. The denominator and rules for incomplete data are therefore important to interpreting a proportion, but they are not reported in the registry record.

Likewise, the registry does not report whether analyses followed an intention-to-treat, per-protocol, or other approach. No such population should be assumed. Without the analysis population, missing-data method, and outcome estimates, readers cannot assess whether the reported safety denominators also apply to the efficacy outcomes or how incomplete follow-up may affect them.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutrophil count decreased (10.0%), hyperglycemia (5.0%), hypertension (5.0%), leukocytosis (5.0%), lung infection (5.0%).

The registry records serious adverse events in the denosumab group for 20 participants at risk, with 6 affected. Other adverse events are recorded for 20 participants at risk, with 20 affected. These are separate registry categories and should not be combined into a new total. The figures describe recorded counts in this single group; they are not a comparative estimate of risk.

The serious adverse-event terms with listed percentages are neutrophil count decreased at 10.0%, and hyperglycemia, hypertension, leukocytosis, lung infection, and somnolence at 5.0% each. The record does not provide further detail in the registry record about severity, timing, duration, recurrence, or whether a listed event was judged related to denosumab. The percentages should therefore be read as registry-reported descriptions, not as evidence of causation.

One death is recorded. These registry entries do not report its cause, timing, or relationship to treatment. A death recorded during a study does not, by itself, establish that the intervention caused it. Because there is no comparator arm, these safety counts also cannot show whether event frequencies were higher or lower than they would have been under another treatment or no treatment.

13. What the Result Does, and Does Not, Mean

The trial addresses a relevant statistical question: whether participants’ risk categories decreased during denosumab treatment, alongside questions about safety and progression. Its primary endpoint is clearly framed as a proportion at 1 year, and the registry specifies the factors used to define risk categories. The record also lists secondary outcomes that distinguish progression events, progression-free survival, skeletal-related events, and bone mineral density change.

What the posted results do not establish is the observed outcome. The primary endpoint result is not reported in the registry record, and results for the listed secondary outcomes are also not reported. There is no reported endpoint proportion or uncertainty interval to assess. The absence of these estimates means that readers cannot determine from this record how many participants had a lower risk category, how precise that estimate would be, or what progression outcomes were observed.

Even if within-group changes were available, the single-group design would not establish that denosumab caused them. Without a comparator, the course of the condition, other care, and measurement variation remain possible explanations. This is a design limitation in interpreting treatment effects, separate from the lack of posted outcome results.

The safety information can be read as descriptive: 6 participants were affected by serious adverse events among 20 at risk, and other adverse events were recorded for 20 participants at risk, with 20 affected. The record also lists one death. These registry entries do not establish causality or provide a comparison with another group.

Thus, the registry documents a completed phase 2 single-group study and its intended measures, along with selected adverse-event counts. It does not supply the efficacy results needed to assess the primary question or to compare denosumab with an alternative. The study’s stated aims should not be confused with demonstrated outcomes: an aim to assess risk or progression is not itself evidence about what occurred.

14. Why This Trial Matters Statistically

This trial illustrates why a well-defined endpoint and a study design suited to the clinical question both matter. The primary endpoint specifies a time point and a rule for classifying risk-category decrease. Its definition lets readers understand what change was intended to be measured. At the same time, a category change is not interchangeable with progression to multiple myeloma, which is listed separately as a secondary outcome.

The single-group design has a clear descriptive role: it can record what happened among participants receiving denosumab. It does not provide a concurrent control for estimating what might have happened without denosumab or under another treatment. This distinction is fundamental when moving from observations over time to claims about treatment effects. A study can be completed and have a defined primary endpoint while still leaving a comparative question unanswered.

Reporting is equally important. Outcome estimates, analysis denominators, and measures of uncertainty allow readers to judge the size and precision of findings. Those primary and secondary outcome results are not reported in the registry record. Without them, the registered endpoints cannot be evaluated as observed findings, and the stated study purpose cannot stand in for results.

The safety counts also show why descriptive reporting should be kept separate from causal interpretation. Events and a death are recorded, but a single-group record cannot provide a treatment comparison, and these registry entries do not establish that an event was caused by the intervention. Transparent definitions and context are necessary for readers to interpret such counts responsibly.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting efficacy is that the primary endpoint result is not reported in the registry record. The same is true for the listed secondary outcomes. No estimate or confidence interval is available in this record to assess the size or precision of any outcome.

The single-group design has no comparator arm. As a result, it cannot support a like-for-like estimate of denosumab’s effect relative to another treatment or no treatment. Changes observed within the group, if available, could not by themselves rule out natural course, other care, or measurement variation as explanations.

The endpoint depends on risk-category classification using specified thresholds. The registry record does not report measurement procedures, the handling of incomplete risk-factor data, or the analysis population. It therefore does not show how participants with missing measurements were handled or which denominator would apply to the primary endpoint.

The registry lists five outcome measures and no analysis entries. It does not report a multiplicity strategy, detailed statistical analysis plan, or protocol-based sample-size justification. The absence of these details limits assessment of how outcomes were prioritized and how any results were intended to be analyzed.

The safety record gives adverse-event counts and selected serious adverse-event terms, but the registry entries do not include event timing, duration, treatment attribution, or further clinical context. One death is recorded without details in the registry record about its cause or relationship to treatment. The safety figures are therefore descriptive and should not be read as comparative or causal evidence.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Denosumab for Smoldering Multiple Myeloma — NCT03839459.
• Registry record last updated 2026-06-15; status last verified 2026-05.
• Results first posted 2023-02-15.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03839459, titled “Denosumab for Smoldering Multiple Myeloma,” is a completed phase 2, single-group study sponsored by the University of Rochester. The registry lists enrollment of 20, no masking, and denosumab as the intervention. The primary endpoint is the proportion of participants with a decreased progression-risk category at 1 year, using three specified risk factors.

Four secondary outcomes address skeletal-related events, progression to multiple myeloma, progression-free survival at 3 years, and bone mineral density change from screening to 1 year. The primary and secondary outcome results are not reported in the registry record. Safety records include 6 participants affected by serious adverse events among 20 at risk, other adverse events among 20 affected out of 20 at risk, and one death. The single-group design does not provide a treatment comparison.